

**Coding Options for Reporting CAR-T Products, Updated as October 1, 2021**

Autologous CAR-T Product Reporting Options <sup>A</sup>	Inpatient Claim - Facility Reporting						Outpatient Claim - Facility Reporting					
	Revenue Code <sup>*</sup>	Notes <sup>^^</sup>	HCPCS Code <sup>**</sup>	HCPCS Product Code Description	Special Instructions for Clinical Trials and Expanded Access Cases <sup>****</sup>	Payment Implications	Revenue Code <sup>*</sup>	Notes	HCPCS Code	HCPCS Product Code Description	Payment Implications	
<b>PRODUCT REPORTING TO MEDICARE</b>	0891 - Special Processed Drugs - FDA Approved Cell Therapy	The charge for the product/drug is typically reported without a HCPCS code on inpatient claims.	Q2041	Axicabtagene ciloleucel, up to 200 million autologous anti cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	For CAR-T cases where the hospital does not incur a cost for the product itself, Medicare will pay a reduced amount of MS-DRG 018.  For clinical trial cases where the CAR-T product is under investigation, report diagnosis code 200.6 and condition code 30 to receive the reduced MS-DRG 018 payment since a CAR-T product cost was not incurred.  For an expanded access case, enter a Billing Note NTE02 "Expand Acc Use" on the electronic claim 8371 or put "Expand Acc Use" in the remarks field on a paper claim (Form Locator 80) to receive the reduced MS-DRG 018 payment since a CAR-T product cost was not incurred. Condition code 90 (effective April 1, 2021) should also be reported by all hospitals to inform CMS services were part of an Expanded Access approval.  For a clinical trial case where the CAR-T product is not under investigation, the provider may enter Billing Note NTE02 "Diff Prod Clin Trial" on the electronic claim 8371 or "Diff Prod Clin Trial" in the remarks field on a paper claim (Form Locator 80) to receive the full MS-DRG 018 payment since a product cost was incurred.	MS-DRG 018 was created to be inclusive of CAR-T costs. NTAP for current CAR-T products expired FY 2021. Product charges are used to determine outlier payments and used in future rate-setting.	0891 - Special Processed Drugs - FDA Approved Cell Therapy	Report appropriate HCPCS code for the product	Q2041	Axicabtagene ciloleucel, up to 200 million autologous anti cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	HCPCS product code generates ASP + 6% reimbursement	
			Q2042	Tisagenlecleucel, up to 600 million car-positive viable t cells, and dose preparation procedures, per therapeutic dose								
			Q2053	Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose								
			Q2054	Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose								
			C9081	Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose								
			C9399 or J3590 and the product NDC until a HCPCS code is released	Other CAR-T products for which there is not an assigned HCPCS code								
<b>PRODUCT REPORTING TO MEDICAID<sup>***</sup></b>	0891 - Special Processed Drugs - FDA Approved Cell Therapy	The charge for the product/drug is typically reported without a HCPCS code on inpatient claims.	Q2041	Axicabtagene ciloleucel, up to 200 million autologous anti cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Check with your payer	Depends on the Medicaid Program.	0891 - Special Processed Drugs - FDA Approved Cell Therapy	Report appropriate HCPCS code for the product	Q2041	Axicabtagene ciloleucel, up to 200 million autologous anti cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Depends on the Medicaid Program	
			Q2042	Tisagenlecleucel, up to 600 million car-positive viable t cells, and dose preparation procedures, per therapeutic dose								
			Q2053	Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose								
			C9076	Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose								
			C9081	Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose								
			C9399 or J3590 and the product NDC until a HCPCS code is released; also check with your payer	Other CAR-T products for which there is not an assigned HCPCS code								
<b>PRODUCT REPORTING TO COMMERCIAL PAYERS</b>	0891 - Special Processed Drugs - FDA Approved Cell Therapy	The charge for the product/drug is typically reported without a HCPCS code on inpatient claims.	Q2041	Axicabtagene ciloleucel, up to 200 million autologous anti cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Check with your payer	Depends on commercial contracts or out-of-network payment.	0891 - Special Processed Drugs - FDA Approved Cell Therapy	Report appropriate HCPCS code for the product	Q2041	Axicabtagene ciloleucel, up to 200 million autologous anti cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Depends on commercial contracts or out-of-network payment	
			Q2042	Tisagenlecleucel, up to 600 million car-positive viable t cells, and dose preparation procedures, per therapeutic dose								
			Q2053	Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose								
			C9076	Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose								
			C9081	Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose								
			C9399 or J3590 and the product NDC until a HCPCS code is released; also check with your payer	Other CAR-T products for which there is not an assigned HCPCS code								

<sup>A</sup> Medicare Special Edition article SE 19009 published May 28, 2019 updates information in the April 2019 OPSS Update Transmittal 4255 where CMS gives providers the option to include cell collection and cell processing charges with the product charge and report all under revenue code 0891. It can be found at <https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/SE19009.pdf>. Value code 86 may be used to report product acquisition cost if requested or allowed by payers.

<sup>^^</sup>In the FY 2021 and FY 2022 IPPS Final Rules, CMS states that there is nothing to preclude hospitals from setting their product charge in accordance with their hospital's cost-to-charge ratio (CCR). Providers should review this and report an appropriate charge as this will impact future MS-DRG 018 rate-setting.

<sup>\*</sup> Revenue code 0891 (an extension of pharmacy 025x or 063x) was created by the National Uniform Billing Committee (NUBC) for reporting special processed drugs - FDA approved cell therapy and includes CAR-T products; see the NUBC manual for more details: <http://www.nubc.org/subscriberonly/PDFs/Cel%20Therapy%20Changes%20August%202018.pdf>. All providers and payers have to use the new codes per the HIPAA transaction code set regulation. Additionally, providers should review the instructions released by CMS in Transmittal R10360CP, effective Oct 5, 2020, to better understand how to report certain instances when a CAR-T product is not incurred (such as expanded access use) as well as when a CAR-T product cost is incurred but the patient is involved in a clinical trial of some other drug. This can be found at: <https://www.cms.gov/files/document/10360cp.pdf>.

<sup>\*\*</sup>HCPCS codes do not typically print on inpatient Medicare claims so product Q-codes or C-codes (which likely will change to a Q-code) are not expected to appear on Medicare inpatient claims despite the codes being shown here unless Medicare instructs differently.

<sup>\*\*\*</sup>Determine specifics of reporting requirements from your state's Medicaid program and the specific patient's Medicaid plan.

<sup>\*\*\*\*</sup>CMS Manual System Pub 100-4 Medicare Claims Processing, Transmittal 10360, from September 18, 2020, section 5, "Payment Adjustment for CAR T-cell Clinical Trial and Expanded Access Use Immunotherapy Cases"

DISCLAIMER: This information was obtained from third-party sources and is subject to change at any time without notice, including as a result of changes in coding, reimbursement, laws, regulations, rules, and policies. Content is informational only, and does not cover all situations or all payers' rules or policies. This document represents no promise or guarantee by ASTCT regarding coverage or reimbursement. The ultimate responsibility for coding and claims submissions lies with the physician, clinician, hospital, and/or other facility. Providers should consult their payers and check bulletins, manuals, program memoranda, and guidelines to ensure compliance with requirements.